Veru (NASDAQ:VERU) Earns “Outperform” Rating from Oppenheimer

Oppenheimer restated their outperform rating on shares of Veru (NASDAQ:VERU) in a research report sent to investors on Monday, Benzinga reports. The firm currently has a $5.00 price target on the stock, down from their prior price target of $7.00.

VERU has been the subject of several other reports. Raymond James assumed coverage on shares of Veru in a report on Thursday, March 28th. They issued an outperform rating and a $3.00 price objective for the company. HC Wainwright restated a buy rating and issued a $2.00 price objective on shares of Veru in a report on Thursday, February 8th.

Veru Trading Up 0.7 %

Veru stock opened at $1.53 on Monday. The firm has a 50-day moving average of $0.68 and a 200-day moving average of $0.74. The firm has a market cap of $223.96 million, a P/E ratio of -2.04 and a beta of -0.22. Veru has a 1-year low of $0.36 and a 1-year high of $1.92.

Institutional Trading of Veru

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its holdings in shares of Veru by 4,643.0% during the second quarter. Goldman Sachs Group Inc. now owns 4,880,509 shares of the company’s stock valued at $55,150,000 after purchasing an additional 4,777,610 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in shares of Veru by 412.4% during the fourth quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company’s stock valued at $4,021,000 after purchasing an additional 4,494,821 shares during the last quarter. Octagon Capital Advisors LP purchased a new position in shares of Veru during the fourth quarter valued at approximately $2,736,000. AIGH Capital Management LLC purchased a new position in shares of Veru during the fourth quarter valued at approximately $2,476,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Veru by 33.1% during the fourth quarter. Vanguard Group Inc. now owns 4,709,876 shares of the company’s stock valued at $3,391,000 after purchasing an additional 1,171,033 shares during the last quarter. 47.16% of the stock is currently owned by hedge funds and other institutional investors.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.